BioRestorative Therapies (BRT) has signed a consulting agreement with Dexterity, to develop and manufacture BRT's proprietary therapeutic delivery device for its intervertebral disc stem cell therapy program, brtxDISC (Disc Implanted Stem Cells).
As per the consulting agreement, Dexterity aims to advance the design and manufacture the disc therapeutic delivery device, towards a final version, to be eventually used in a clinical trial as a stem cell delivery system for the treatment of bulging and herniated discs.
The brtxDISC program is developed as an alternative to surgical treatment for the patients suffering from bulging or herniated discs and could bridge the gap between non-invasive and invasive surgical back procedures.
Dexterity president Eric Simon said, "Our experience with laparascopic and catheter-based devices, cell culture systems, and drug-delivery devices will assist in advancing the development and production of BRTX’s disc stem cell delivery device as the company moves through its next phase of clinical trials."
BioRestorative Therapies CEO Mark Weinreb said with Dexterity’s depth of experience in 3D-CAD, biomaterials, and advanced prototyping and manufacturing, they are the perfect partner to work on the design and final engineering of BRT’s medical disc delivery device.
"We are confident our device will have the performance and quality to operate as intended and will be commercial-ready when we are able to launch our brtxDISC program," Weinreb added.
The therapy is a regeneration repair process that uses patient’s own stem cells that are implanted using BRT’s proprietary therapeutic delivery device.